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ABSTRACT
Translesion DNA synthesis (TLS) employs
low-fidelity DNA polymerases to bypass replication-
blocking lesions, and being associated with
chromosomal replication was presumed to occur
in the S phase of the cell cycle. Using immuno-
staining with anti-replication protein A antibodies,
we show that in UV-irradiated mammalian cells,
chromosomal single-stranded gaps formed in S
phase during replication persist into the G2 phase
of the cell cycle, where their repair is completed de-
pending on DNA polymerase f and Rev1. Analysis of
TLS using a high-resolution gapped-plasmid assay
system in cell populations enriched by centrifugal
elutriation for specific cell cycle phases showed
that TLS operates both in S and G2. Moreover, the
mutagenic specificity of TLS in G2 was different
from S, and in some cases overall mutation fre-
quency was higher. These results suggest that TLS
repair of single-stranded gaps caused by DNA
lesions can lag behind chromosomal replication, is
separable from it, and occurs both in the S and G2
phases of the cell cycle. Such a mechanism may
function to maintain efficient replication, which can
progress despite the presence of DNA lesions, with
TLS lagging behind and patching regions of
discontinuity.
INTRODUCTION
Translesion DNA synthesis (TLS) is a DNA damage tol-
erance mechanism that assists replication to overcome
blocking lesions. It is inherently mutagenic due to the
miscoding nature of most DNA lesions, and the
promiscuous active site of the TLS DNA polymerases
involved in the process (1–4). Despite its inherent muta-
genic nature, TLS has a major role in protecting humans
against DNA damage, as indicated by the high sunlight
sensitivity and skin cancer pre-disposition of individuals
with germ-line mutations, which inactivate the TLS DNA
polymerase (pol) Z (5,6). Mammalian cells contain
multiple TLS polymerases (7), which exhibit a certain
degree of DNA damage speciﬁcity and act largely via
two-polymerase mechanisms in which insertion opposite
the lesion is carried out by one polymerase, and extension
past the lesion by a second polymerase, usually polz (2,8–
10). The DNA sequence resulting from TLS is largely
determined by the inserter DNA polymerase (2,8). TLS
is tightly regulated at several levels to prevent an escal-
ation in mutation rates. This includes monoubiquitination
of proliferating cell nuclear antigen (PCNA), which is
induced by DNA damaging agents and serves to recruit
TLS polymerases to the damaged site in DNA (11–13), as
well as the p53 and p21 proteins, which restrain TLS and
make it more accurate (14).
TLS was believed to be associated with DNA replica-
tion, and therefore, to occur in the S phase of the cell cycle
(15). However, it was shown that DNA replication skips
template regions containing lesions formed by damaging
agents such as ultraviolet (UV) radiation, leaving behind
single-stranded DNA (ssDNA) gaps (16–19). The repair of
these gaps was termed post-replication repair, suggesting
that it occurs behind the replication fork. However, to
which extent does TLS lag behind replication forks, and
whether it is conﬁned to the S phase of the cell cycle was
largely unexplored. Recently, studies from two labs
demonstrated that TLS can occur in the G2 phase of the
cell cycle in the yeast Saccharomyces cerevisiae, suggesting
that TLS is separable from chromosomal replication
(20,21). Here, we describe our study of the operation of
TLS along the various cell cycle phases in mammalian
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high or higher in G2 compared to S phase, indicating that
it lags behind chromosomal replication. Moreover, the
mutagenic signature in G2 was different than in S, and
the overall mutation frequency was higher for some
lesions.
MATERIALS AND METHODS
Cell lines, DNA constructs and antibodies
The U2OS cell line was derived from human osteosar-
coma. Wild-type mouse embryonic ﬁbroblasts (MEF)
were previously described (18). Cells were maintained in
Dulbecco’s Modiﬁed Eagle’s Medium (DMEM) supple-
mented with 2mM glutamine. The medium was supple-
mented with 10% fetal bovine serum, 100U/ml of
penicillin and 100mg/ml streptomycin. Cells were
incubated at 37 C in a 5% CO2 atmosphere. The construc-
tion of gapped plasmids carrying site-speciﬁc TT CPD, TT
6-4PP, cisPt-GG or BP-G was previously described (8,22).
Sources of antibodies were as follows: mouse monoclonal
anti-polZ antibody (B-7): sc-17770 (used at a dilution of
1:200 in western blot, Santa Cruz Biotechnology); rabbit
polyclonal anti-pol Iota NB100-175 (used at a dilution of
1:500 in western blot, Novus Biologicals); anti-Rev1
Rabbit polyclonal (used at a dilution of 1:500 in western
blot, a generous gift from Sam H. Wilson, NIEHS, NC,
USA) (23); rabbit polyclonal anti-cyclinA (H-432):sc-751
(used at a dilution of 1:1000 in western blot, Santa Cruz
Biotechnology); mouse anti-replication protein A (RPA)-
32/RPA-2 [used at a dilution of 1:500 for immuno-
ﬂouresence, AbCam (cat. no: ab2175)]; mouse monoclonal
anti-PCNA, PC-10 (used at a dilution of 1:1000 in western
blot, Sigma); mouse anti-tubulin, (DM1A, Sigma); anti-
p21 antibody (F5 or C19, Santa Cruz Biotechnology);
Rabbit polyclonal anti g-Tubulin (ab11317, used at a
dilution of 1:2000 for immuno-ﬂouresence, Abcam).
Fractionation of cells in the G1, S and G2 phases of
the cell cycle
Human U2OS cells or mouse embryo ﬁbroblasts were
fractionated by centrifugal elutriation as described (24),
using a J6 Beckman elutriation centrifuge with a JE-5.0
rotor equipped with a single-standard 5ml elutriation
chamber (Beckman Coulter, Inc., Fullerton, CA, USA)
and a masterﬂex microprocessor pump drive, model
7524-05 (Cole Parmer).
Analysis of RPA foci by ﬂuorescence microscopy
For RPA immunostaining, cells were seeded on 13-mm
glass cover slips coated with 0.01% poly-L-lysine
(Sigma). After 90min of the cells attaching to the slides,
the medium was removed and the cells were UV-irradiated
at 254nm using a low-pressure mercury lamp at doses of
1–10J/m
2. The dose rate was determined by a
UV-products radiometer using a UVX-25 sensor. At
various time points, cells were washed three times with
PBS, pre-extracted in 25mM HEPES pH 7.4, 50mM
NaCl, 3mM MgCl2, 300mM sucrose, 0.5% Triton
X-100 for 5min on ice with gentle shaking and washed
three more times with PBS. The slides were then ﬁxed with
4% paraformaldehyde for 15min at room temperature,
and washed three times in PBS. Blocking was done in
PBS supplemented with 5% normal goat serum (Sigma)
for 30min at room temperature. The cells were incubated
for 1h with anti-RPA32 mouse antibodies at a dilution of
1:500, and anti g-tubulin rabbit antibodies at a dilution of
1:1000. After the incubation, the slides were washed three
times in PBS and incubated with a secondary goat
anti-mouse Alexa Fluor 488 (green) antibody (Jackson,
diluted 1:1000) and goat anti-rabbit cy3 (Jacskon,1:2000)
and with 40,6-diamidino-2-phenylindole (DAPI) diluted
1:1000 for 45min. The slides were then washed three
times in PBS and mounted on microscope slides using
Prolong gold reagent (Invitrogen). Images were captured
with a DeltaVision system (Applied Precision) equipped
with an Olympus IX71 microscope. Optical images were
acquired using CCD camera (Photometrics, Coolsnap
HQ) and a  60/1.42 objective (Olympus). To determine
the fraction of RPA positive cells, the number of cells in
each ﬁeld was counted by the DAPI stain and then the
ﬁlter was changed and RPA positive cells were counted. In
each sample, at least 10 ﬁelds and 100 cells were scored.
Similarly, in order to determine the cell cycle state of RPA
positive cells. The RPA positive cells in each ﬁeld were
counted and then the ﬁlter changed, and the centrosome
state in each cell was determined by g-tubulin staining. In
experiments with siRNA treatment, U2OS cells were
transfected with 10nM siRNA oligos (Darmacon,
siGENOME) in 15cm plates, at 30% conﬂuence. After
48h, the cells were split to new plates, and after 24 add-
itional h (total of 72h with siRNA), the cells were
synchronized by centrifugal elutriation, UV-irradiated
and then analyzed for RPA foci and cell cycle progression.
TLS assay in elutriation-fractionated cells
The TLS assay was done as previously described (8,14,22)
with some minor changes. In each transfection,
1–1.5 10
6 U2OS or MEF cells were electroporated
using Amaxa Nucleofector Device (Lonza,
Switzerland). The transfected DNA was a mixture
composed of the following: 100–200ng of a gapped-lesion
plasmid (bearing a kan
R cassette), 100–200ng of a gapped
plasmid without lesion (bearing a cm
R cassette) and 5mg
of the carrier plasmid pUC18. After the incubation time
(indicated separately for each experiment), the cells were
harvested and plasmid DNA was extracted using a
plasmid extraction kit (RBC biosciences, Taiwan). The
DNA was transformed into a TLS-deﬁcient Escherichia
coli recA strain by electroporation and plated on LB
plates containing either kanamycin or chloramphenicol.
The percentage of lesion–plasmid survival was calculated
by dividing the number of transformants obtained from
the gap-lesion plasmid (number of colonies on LB-kan
plates) by the number of corresponding transformants
obtained with the control gapped plasmid GP20-cm
(number of colonies on LB-cm plates). Plasmids were ex-
tracted from kan
R colonies, and the sequence opposite the
lesion was determined using Bigdye Terminator V1.1
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using 3130XL genetic analyzer (Applied Biosystems,
USA). To obtain values of TLS from values of gap
repair, the latter were multiplied by the percentage of
TLS events out of the total events, as determined by the
DNA sequence analysis.
RESULTS
RPA foci are formed in the S phase in UV-irradiated
human cells
Seeking to determine the activity of TLS during the cell
cycle, we analyzed the formation and disappearance of
ssDNA regions in UV-irradiated human cells during
chromosomal replication. Such regions represent replica-
tion forks arrested at sites of UV damage, and gaps
whereby replication skipped over UV damage [post-
replication gaps; reviewed in (25)]. To measure these
ssDNA regions, we used immunoﬂuorescence staining of
RPA foci (26). RPA is a trimeric protein that speciﬁcally
binds ssDNA, and is essential for DNA replication as well
as other DNA transactions (27). As can be seen in
Figure 1A, staining of RPA in the nuclei of unirradiated
human U2OS cells was scarce. In contrast, after UV
irradiation at 10J/m
2, the majority of nuclei exhibited
robust formation of RPA foci (Figure 1A). To concentrate
on gaps formed by UV during replication, we used the
UV-irradiated cells that were enriched for the G1/S
boundary stage by centrifugal elutriation, using cells in
the G1 phase as a control. The advantage of centrifugal
elutriation for isolating cells at the various cell cycle stages
is that it does not involve any drugs, and therefore likely
to be free of any interfering effects.
U2OS cells were fractionated by centrifugal elutriation,
and fractions at G1 or at the G1/S boundary were
UV-irradiated at 3J/m
2 (43% survival; Supplementary
Figure S1A) allowed to grow for 2h, and then ﬁxed and
immunostrained for RPA. As can be seen in Figure 1B,
unirradiated cells contained a low background of RPA
foci, as expected, since the abundance of persisting
ssDNA regions in the absence of DNA damage was low.
G1-irradiated cells also exhibited a low level of RPA
foci, consistent with the lack of replication during this
cell cycle stage (Figure 1B). In contrast, when cells were
irradiated at the G1/S boundary, the percentage of cells
with RPA foci increased compared to cells irradiated at
G1 (Figure 1B), suggesting that the staining of RPA
reﬂects ssDNA regions that were formed during S phase.
UV-induced RPA foci formed during S phase disappear
primarily in the G2 phase
To follow the fate of UV-induced RPA foci, we irradiated
human U2OS cells at the G1/S boundary with a UV dose
of 3J/m
2, and then monitored in parallel cell cycle pro-
gression and RPA foci for up to 32h post-irradiation. As
can be seen in Figure 1C, UV irradiation at this UV dose
caused a delay in cell cycle progression, which recovered
by 32h (Figure 1C). Under these conditions, the number
of cells with RPA foci increased for up to 8h
post-irradiation, then declined, reaching the background
level by 24h (Figure 1D). This behavior is consistent with
an accumulation of replication gaps, followed by DNA
damage tolerance that restored the double-stranded struc-
ture. Strikingly, RPA foci disappeared 16–24h after ir-
radiation, a time period in which most of the cells were
in G2 (Figure 1D). To directly examine whether RPA foci
exist in cells that are in G2, we performed double staining
for RPA and the centrosomic protein g-tubulin, which can
be used as a marker for cells in G2 (28). After verifying
that the cell cycle distribution as predicted by g-tubulin
correlates with that reﬂected in the ﬂuorescence-activated
cell sorting (FACS) analysis (Supplementary Figure S1B),
we determined the cell cycle distribution of RPA positive
cells. As can be seen in Figure 1E, about half of the RPA
positive cells were in G2, indicating that a signiﬁcant
fraction of UV-induced gaps were not ﬁlled in during S
and entered G2, where they were later ﬁlled in. Repeating
the experiment with cells irradiated at 10J/m
2 revealed a
severe arrest at G2, massive cell death (Supplementary
Figure S1C) and persistence of RPA foci
(Supplementary Figure S1D).
Disappearance of RPA foci is dependent on the TLS
DNA polymerase f and Rev1
To examine whether the disappearance of RPA foci in
U2OS cells had occurred by TLS, we knocked down the
expression of the REV3L gene encoding the catalytic
subunit of DNA polymerase z (Supplementary
Figure S2D), and followed the formation and disappear-
ance of RPA foci after UV irradiation. As can be seen in
Figure 2A, UV irradiation of the cells at the G1/S
boundary caused a delay in cycle progression, which was
more pronounced for cells treated with REV3L siRNA
compared to control siRNA (Figure 2A). Analysis of
RPA foci showed that 12h after irradiation of cells
treated with a control siRNA, RPA foci were abundant,
but most of them disappeared by 20h after irradiation
(Figure 2B). In contrast, in cells treated with REV3L
siRNA, RPA foci persisted also at 20h after irradiation
(Figure 2B). Background levels of RPA foci were observed
in unirradiated cells, possibly the result of replication gaps
caused by background DNA damage. The quantiﬁcation
of the analysis is shown in Figure 2C. In cells treated with
the control siRNA, the number of RPA foci was reduced
to background level by 20h after irradiation, with 6.5% of
the cells exhibiting RPA foci. In contrast, when expression
of REV3L was knocked down, there was a strong inhib-
ition in disappearance of RPA foci, with 37% of the cells
still containing RPA foci 20h after irradiation, >5-fold
higher than the control cells (Figure 2C). Performing
similar experiments with U2OS cells in which the expres-
sion of REV1 was knocked down (Supplementary
Figure S2C), showed generally a similar result, although
the inhibition in the disappearance of RPA foci was milder
(Figure 2D and Supplementary Figure S2). These data
indicate that TLS is involved in the disappearance of
RPA foci, consistent with a previous report that TLS is
the main mechanism for ﬁlling in post-replication DNA
gaps in mouse cells (18). Moreover, the data show that
polz and REV1 have a major role in the repair of
172 Nucleic Acids Research, 2012,Vol. 40,No. 1chromosomal ssDNA gaps in human cells, consistent with
previous studies carried out with mouse cells (18,29). The
ability to follow by RPA staining the repair of chromo-
somal UV-induced replication gaps adds a signiﬁcant tool
to the currently available DNA damage tolerance assays.
Analysis of the expression of TLS proteins at various
cell cycle stages
We analyzed the expression of three TLS polymerases at
the various cell cycle stages: polZ and poli and Rev1, a
TLS regulatory protein with restricted dCMP transferase
activity (18,30), which was reported to be highly induced
in G2 in S. cerevisiae (31). This was done in human U2OS
cell fractions enriched by centrifugal elutriation for the
G1, S or G2 phases of the cell cycle. As can be seen in
Figure 3A, immunoblot analysis showed no signiﬁcant
differences in the amounts of these polymerases at the
various cell cycle stages, although there appeared to be a
mildly higher amount of polZ in G2. Analysis of mRNA
expression by real-time polymerase chain reaction (PCR)
showed a mild increase in polZ mRNA from G1 through
S to G2 (Figure 3B), whereas, the levels of Rev1 mRNA
were similar (Figure 3C). We have also determined the
amount of monoubiquitinated PCNA (Ub-PCNA)
Figure 1. Formation and disappearance of RPA foci following UV irradiation. (A) RPA foci. U2OS cells were irradiated at 10J/m
2 UV, ﬁxed after
2h and immunostained with anti-RPA antibodies. (B) Formation of RPA foci during replication of UV-irradiated cells. U2OS cell populations at G1
and at the G1/S transition were irradiated at 3J/m
2 UV, ﬁxed after 2h and immunostained for RPA. In this experiment and all subsequent RPA
staining experiments, quantiﬁcation was done by ﬁrst detecting cells by DAPI staining and then scoring positive or negative for RPA foci.
Approximately 150 cells were scored for each sample. (C) Cell cycle proﬁles of U2OS cells with or without UV irradiation at 3J/m
2.
(D) Kinetics of RPA foci formation and clearance after 3J/m
2 UV treatment. Values of RPA positive cells at each time point are compared
with the portion of cells in the G2 phase in the irradiated population. (E) Analysis of cell cycle distribution of RPA foci-positive cells 16h after
UV irradiation at 3J/m
2. Cells were co-stained for RPA (green) and g-tubulin (red). g-Tubulin stains the centrosomes, and is used to determine the
cell cycle status. G2 cells have fully duplicated and separated centrosomes, which appear as two distinct red dots.
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DNA following DNA damage. In unirradiated cells
ubiquitinated PCNA was undetectable (Figure 3D). In
UV-irradiated cells, soluble PCNA was not modiﬁed,
but chromatin-bound PCNA was monoubiquitinated, as
expected. However, the levels of Ub-PCNA appears to be
similar in all cell cycle stages (Figure 3D), suggesting that
the cell cycle regulation of TLS is not determined by
Ub-PCNA per se. Ub-PCNA was present also in the G1
phase, suggesting that in UV-irradiated cells, PCNA is
monoubiquitinated also in the absence of replication.
TLS is as high or higher in G2 compared to the S phase
of the cell cycle
To directly measure TLS during the different phases of the
cell cycle, we utilized a quantitative TLS assay based on
gapped plasmids carrying a gap opposite a deﬁned and
site-speciﬁc lesion. This gapped plasmid assay has been
extensively used in our laboratory, and proved to be a
powerful model for TLS, exhibiting dependence on the
polymerase composition of cells and being subject to regu-
lation in a manner similar to that observed in chromosom-
al TLS (8,14,22,33,34).
The experimental scheme is outlined in Figure 4A.
Human U2OS cell fractions enriched for the G1, S or
G2 phases of the cell cycle were isolated by centrifugal
elutriation, and transfected with a gapped plasmid
carrying a site-speciﬁc lesion in a single-stranded region,
along with a control gapped plasmid with no lesion.
Transfection was carried out by electroporation in order
to facilitate rapid entry of the plasmids into the cell
nucleus. The cells were incubated for 1–1.5h to allow
time for gap ﬁlling via TLS to occur, after which the
plasmid content was extracted and assayed for TLS.
Figure 2. Time course of cell cycle status and RPA foci in UV-irradiated cells in which the expression of DNA polymerase z or Rev1 was knocked
down. (A) Cell cycle proﬁles of U2OS cells treated with siControl or siREV3L (encoding the catalytic subunit of polz) with or without UV irradiation
at 3J/m
2.( B) Representative images of UV-irradiated and unirradiated cells, in which the expression of polz was knocked down by treatment with
REV3L siRNA. Staining was done with DAPI (blue) and anti-RPA2 antibodies (green). (C) Time course of RPA foci clearance 12–20h after 3J/m
2
UV treatment. Unirradiated cells treated with siControl (ﬁlled diamond) or siREV3L (ﬁlled square) were compared to UV-irradiated cells treated
with siControl (ﬁlled triangle) or siREV3L (ﬁlled circle). (D) RPA foci clearance after 3J/m
2 UV treatment of U2OS cells that were pre-treated with
REV1 siRNA or control siRNA. See Supplementary Figure S2 for RPA foci images and cell cycle analysis.
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during this short time window that was used to assay TLS
(Figure 4B). Figure 4C and Supplementary Tables S3 and
S4 show the results of a TLS experiment performed with a
gapped plasmid carrying a site-speciﬁc thymine–thymine
cyclobutane pyrimidine dimer (TT CPD), the main UV
lesion in DNA. TLS in U2OS cells enriched for the S
phase was 42%,  2-fold higher than during G1. When
measured in G2, TLS was even higher, amounting
to 62%. To examine the situation in another cell type,
we used mouse embryo ﬁbroblasts (MEF). We found
that in these cells TLS across a TT CPD in G2 was
57%, compared with 34% and 15% in S and G1, respect-
ively (Figure 4C and Supplementary Table S4).
We also tested TLS across another lesion, an
intrastrand cisplatin-GG adduct (cisPt-GG), the main
DNA lesion caused by the chemotherapy drug cisplatin.
As can be seen in Figure 4D and Supplementary Tables S3
and S4, similarly to the bypass of the TT CPD, TLS across
cisPt-GG was higher in G2 and S than in G1 in both
Figure 3. Analysis of cell cycle-dependent expression of TLS polymerases and PCNA ubiquitination. (A) U2OS cells were fractionated by centrifugal
elutriation to fractions enriched for speciﬁc cell cycle phases, and analyzed for expression levels of PolZ, Poli and Rev1 using western blot analysis.
(B) Analysis of polZ mRNA levels at different cell cycle stages using real-time PCR. (C) Analysis of mRNA levels of Rev1 at different cell cycle
stages using real-time PCR. (D) Analysis of PCNA monoubiquitination at different cell cycle stages. U2OS cells were separated to fractions enriched
for speciﬁc cell cycle phases, UV-irradiated (20J/m
2), and 4h later soluble (left panel; triton soluble) and chromatin-bound (right panel; triton
insoluble) proteins were extracted and analyzed for the extent of PCNA monoubiquitination (Ub-PCNA) using anti-PCNA antibodies.
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chinery appears to remain functional also in the G1 phase.
Different mutagenic signature and lower ﬁdelity of
TLS in G2 compared to S
DNA sequence analysis of the plasmids allowed us to de-
termine the accuracy and error spectrum of TLS at the
various cell cycle stages. As can be seen in Figure 5A
and Supplementary Table S4, TLS across cisPt-GG in
MEF was largely accurate, consistent with previous
results (8). However, the overall error frequency was not
uniform throughout the cell cycle. Thus, out of the TLS
events, the error frequency at the cisPt-GG lesion in G2
was 8%,  3-fold higher than in S (2.8%; P=0.032,  
2
test). The same analysis in human U2OS cells revealed a
similar trend (Figure 5A and Supplementary Table S3).
We analyzed the mutagenic signature of two additional
lesions in MEF cells. As can be seen in Figure 5B and
Supplementary Table S4, the overall mutagenicity of
TLS across a thymine–thymine 6-4 photoproduct (TT
6-4PP), a highly mutagenic UV lesion, was similar at the
various cell cycle stages. However, there were differences
in the mutagenic signatures (Figure 5B and
Supplementary Table S4). Most notable, the
AAC!AAA hotspot mutation, a hallmark mutation of
TT 6-4PP (34,35), was much more prevalent in G2 (19.4%
of all TLS events) compared with S (9.3% of all TLS
events; P=0.008,  
2 test), and G1 (3.7% of all TLS
events; P=0.00001,  
2 test). When studying BP-G [the
(+)–trans-BPDE N
2-guanine adduct], a major tobacco
smoke adduct, overall mutagenic TLS was similar in the
various cell cycle stages and accounted for 10–15% of all
TLS events (Figure 5C and Supplementary Table S4).
However, like in the case of the TT 6-4PP, there was a
difference in mutagenic signature at the various cell cycle
stages (Figure 5C and Supplementary Table S4) Thus, the
C!A mutation opposite the BP-G accounted for 8.5% of
all TLS events in G2, but only 1.8% in S (P=0.021,  
2
test) and <1% in G1 (P=0.0045;  
2 test).
DISCUSSION
Regions of ssDNA caused by interruption of replication at
DNA lesions can be repaired to yield a double-stranded
conﬁguration by one of the two known tolerance mechan-
isms, namely TLS, or homology-dependent repair (HDR),
which includes homologous recombination repair (HRR)
and template switch recombination (16,36–40). The
B A
CD
Figure 4. Translesion DNA synthesis in G2 is as high or higher than in S phase. TLS efﬁciency across DNA lesions in human and murine cell lines
was measured using the gapped plasmid assay system. (A) A schematic representation of the experimental system. (B) A representative sample of the
cell cycle fractions that were collected by centrifugal elutriation, and subsequently used for the TLS experiments shown below. Samples that were
analyzed by ﬂow cytometry were ﬁrst mock transfected to mimic the treatment used in the TLS assay. Analysis of TLS was performed at the various
cell cycle stages for TT CPD (C) and cisPt-GG (D). Each graph represents the average of at least three independent experiments. The detailed
numerical results are presented in Supplementary Tables S3 and S4.
176 Nucleic Acids Research, 2012,Vol. 40,No. 1relative contribution of each of these tolerance pathways is
not precisely known due to the scarcity of appropriate
assays. In mammals, TLS appears to play a major role
in ﬁlling in of replication gaps caused by UV lesions as
indicated by the severe phenotype of xeroderma
pigmentosum variant patients who lack the TLS polymer-
ase Z (3), and by the essentiality in mice of Rev3L, the
protein encoding the catalytic subunit of DNA polymer-
ase z, a key TLS polymerase (41). In addition, studies
performed in UV-irradiated mouse cells suggest that
TLS is the dominant mechanism for ﬁlling-in these
post-replication DNA gaps (18). Thus, the disappearance
of the RPA foci in G2 is consistent with the operation of
TLS to ﬁll in these gaps.
The activity of TLS is determined by cis-acting DNA
elements, e.g. the gaps formed in damaged DNA, as well
as trans-acting factors, i.e. TLS proteins. Using the
gapped plasmid TLS assay system enabled us to probe
the cellular composition of the TLS machinery at the
various cell cycle stages, since this assay monitors the op-
eration of trans-acting factors on the plasmid. The results
presented above, clearly indicate that the components of
the TLS machinery change throughout the cell cycle, and
exhibit their greatest activity during S and G2. The essence
of these changes is unknown yet, but they do not seem to
involve changes in the expression levels of the TLS
polymerases Z, i and Rev1. In addition, there seemed to
be no signiﬁcant change in the ubiquitination of PCNA,
which functions to recruit TLS polymerases to damaged
sites in the DNA. Other possible regulatory mechanisms
such as subcellular localization, post-translational modiﬁ-
cations or the involvement of other regulatory proteins
have not been addressed yet. The TLS machinery
appears to remain functional also in the G1 phase,
although we cannot rule out the possibility that some of
this TLS occurs in the small fraction of early S phase cells
that may be present in the G1 cells preparation. The ex-
istence of the TLS machinery in G1 is not particularly
surprising, as it may function to ﬁll in gaps that were
formed by opposite lesions, e.g. by incidental strand dis-
placement and excision reactions, or during the ﬁrst step
of interstrand crosslink repair. In addition, the TLS
enzyme DNA polymerase k was reported to function
also in nucleotide excision repair, which operates in G1
(42). This is consistent with the presence of Ub-PCNA
during G1 in UV-irradiated cells.
Interestingly, the mutagenic signature of TLS varied
during the cell cycle. Notably, TLS across cisPt-GG was
more mutagenic in G2 compared with S, both in human
U2OS and MEF cells. TLS across TT 6-4PP and BP-G
exhibited similar extent of mutagenicity in G2 and S;
however, there were marked differences in mutagenic
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Figure 5. TLS speciﬁcity at the various cell cycle phases. TLS experiments were performed in cells enriched for deﬁned stages of the cell cycle using
the gapped plasmid assay system as described in the legend to Figure 4, after which plasmids were subjected to DNA sequence analysis at the region
of the lesion. (A) TLS across cisPt-GG is more mutagenic in the G2 phase than in the G1 phase or S phase in MEF (gray bars) or U2OS cells (dark
bars). (B) The overall mutagenicity of TLS across TT 6-4PP is similar in the various cell cycle phases (dark bars), but the mutagenic signature was
different. For example, the prevalence of the hotspot mutation AAC!AAA (gray bars) in G2 is higher than in G1 or S. (C) The overall
mutagenicity of TLS across BP-G is similar in the various cell cycle phases (dark bars), but the mutagenic signature is different. For example,
the prevalence of the C!A mutation (gray bars) opposite BP-G in G2 was higher than in G1 or S. The detailed numerical results are presented in
Supplementary Tables S3 and S4. *, statistically signiﬁcant measurements. P-values are presented in the text.
Nucleic AcidsResearch, 2012, Vol.40,No. 1 177speciﬁcity. Speciﬁcally, the AAC!AAA hallmark
mutation at TT 6-4PP was more prevalent in G2 than in
S, and the C!A transversion at BP-G was much more
prevalent in G2 than in S. We have previously shown that
Rev1 is required for the formation of the AAC!AAA
hotspot mutation in mammalian cells (18), and therefore
the large increase in the abundance of this mutation in G2
observed here is consistent with the action of Rev1 in
post-replication gaps in G2. Taken together, these data
support the notion that the composition of the TLS ma-
chinery changes along the cell cycle, which in some cases
leads to more mutagenic TLS in G2. This may reﬂect an
urgency in gap-ﬁlling as cells get close to mitosis, mani-
fested by the activation of less accurate backup TLS
pathways, and may explain the higher mutation rates
observed at late replication times, when cells are closer
to G2. This phenomenon was observed in both human
(43) and S. cerevisiae cells (44) and in the latter, was
shown to depend on TLS.
It could have been envisioned that lesions on the con-
tinuously synthesized leading strand arrest replication
forks, whereas on the lagging strand, which is synthesized
in a discontinuous manner, lesions cause the formation of
gaps, because synthesis can reinitiate downstream of the
lesion by a new Okazaki fragment. However, there is
evidence from studies in S. cerevisiae (17) and E. coli
(45,46) indicating that the presence of lesions can lead to
gap formation on both the lagging and the leading
strands, through replication reinitiation downstream of
the lesions. Moreover, a recent study provided evidence
for effective repriming past UV lesions during replication
in human cells, leaving gaps opposite the lesions (47).
Thus, one may envisage a situation in which the
majority of replication discontinuities are gaps rather
than arrested forks. When forks are arrested at lesions,
relief of the block is likely to occur rather promptly, to
prevent fork collapse and the formation of double-strand
breaks, which are severe lesions. This implies that in such
cases, lesion bypass would operate in the S phase. In
contrast, there is less urgency in ﬁlling in replication
gaps, the formation of which has little effect on replication
fork progression in mammalian cells (18,47). Accordingly,
TLS gap ﬁlling may start in S, but reaches its maximum in
G2. In S. cerevisiae, a strongly increased expression of
Rev1 (31) is likely to be involved in the higher TLS in
G2. This is not the case in human cells, where the expres-
sion of Rev1 is not increased in G2 (Figure 3). Rev1 may
still be involved by undergoing activation in G2, e.g. by
post-translational modiﬁcation, but other mechanisms
may be involved as well.
At ﬁrst glance, a strategy of postponing TLS up to late
S and G2 appears to be a dangerous choice in mammalian
cells, because that would mean having single-stranded
regions exposed for a prolonged time, which increases
the risk of producing highly deleterious double-strand
breaks. Yet, the data presented here does indicate that
TLS lags behind replication, and ﬁnishes its operation in
G2 (Figure 6). We suggest that this mechanism ensures
that chromosomal replication, which is an immense task,
continues its operation with minimal delay, leaving behind
the ‘road repair work’ of local patching of gaps. This gap
repair can continue during G2, but apparently must be
completed before the cell enters mitosis. The in-depth
analysis of this mechanism may help to elucidate the in-
volvement of TLS, and in particular, that of mutagenic
TLS, in pathogenic processes, primarily carcinogenesis,
where the formation of mutations plays a critical role.
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